Erymax 250mg (Erythromycin delayed-release 250 mg)
Pill imprint Erymax 250mg has been identified as Erythromycin delayed-release 250 mg.
Erythromycin is used in the treatment of dental abscess; skin or soft tissue infection; upper respiratory tract infection; bronchitis; nongonococcal urethritis (and more), and belongs to the drug class macrolides. There is no proven risk in humans during pregnancy. Erythromycin 250 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Imprint:
- Erymax 250mg
- Strength:
- 250 mg
- Color:
- Orange / Clear
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- Macrolides
- Pregnancy Category:
- B - No proven risk in humans
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Midlothian Laboratories
More about erythromycin
Consumer resources
- Erythromycin
- Erythromycin base and stearate
- Erythromycin delayed-release capsules
- Erythromycin delayed-release tablets
- Erythromycin ethylsuccinate
- More (5) »
- Other brands: Erythrocin, Ery-Tab, Ilosone, PCE Dispertab, More (7) »
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
